Why the study?
Does aliskiren/amlodipine single-pill combination improve blood pressure reduction in patients with mild-to-moderate hypertension non-responsive to aliskiren monotherapy?
Does aliskiren/amlodipine single-pill combination improve blood pressure reduction in patients with mild-to-moderate hypertension non-responsive to aliskiren monotherapy?
Aliskiren/amlodipine single-pill combinations offer an effective step-up therapy for patients with hypertension inadequately controlled on aliskiren monotherapy.
Answers are grounded in this paper and cite their sources.
Aliskiren/amlodipine SPCs offer effective step-up therapy for aliskiren non-responders; extends RCT evidence for dual therapy in hypertension.
Many patients with hypertension will require multiple antihypertensive drugs to achieve blood pressure (BP) control. This double-blind study evaluated the efficacy and safety of aliskiren/amlodipine single-pill combinations (SPCs) in patients with mild-to-moderate hypertension who were non-responsive to aliskiren monotherapy. After a 4-week run-in with aliskiren 300 mg, patients with mean sitting diastolic BP (msDBP) ≥ 90 and < 110 mmHg were randomized to oncedaily aliskiren/ amlodipine 300/10 mg or 300/5 mg, or aliskiren 300 mg for 8 weeks. Aliskiren/amlodipine SPCs provided significantly greater mean reductions in mean sitting systolic BP/msDBP (300/10 mg, 18.0/13.1 mmHg; 300/5 mg, 14.4/10.5 mmHg) than aliskiren 300 mg (6.4/5.8 mmHg) at week 8 endpoint. This represents additional mean reductions of 11.6/7.2 mmHg (300/10 mg) and 8.0/4.7 mmHg (300/5 mg) over aliskiren alone (both p < 0.0001). Significantly more patients achieved BP control ( < 140/90 mmHg) with aliskiren/amlodipine 300/10 mg (65.5%) and 300/5 mg (56.6%) than with aliskiren (31.5% both p < 0.0001). Aliskiren, alone and in combination with amlodipine, was well tolerated, with a slightly higher incidence of adverse events with SPCs (29.0-30.1%) than with monotherapy (22.7%). In conclusion, aliskiren/amlodipine SPCs offer an effective next step for patients who have an inadequate BP response to aliskiren alone.
No takes yet. Share an insight, caveat, or question.
Glorioso et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: